dpp4 vs glp 1 GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes Target Trial of Glucagon-Like Peptide-1

Continuous use without cycling can lead to receptor desensitization, diminishing returns, and unknown long-term effects

Personalized nutrition by prediction of glycemic responses

Researchers continue to investigate how these interconnected pathways contribute to normal metabolic function and cellular physiology

Overcooking makes it mushy

Legal Framework FDAs announcement renews focus on the boundaries between traditional pharmacy compounding under Section 503A, bulk compounding under 503B and drug manufacturing requiring FDA approval

Gut microbiota and oral contraceptive use in overweight and obese patients with polycystic ovary syndrome